VicetonThis page contains information on Viceton for veterinary use.
The information provided typically includes the following:
- Viceton Indications
- Warnings and cautions for Viceton
- Direction and dosage information for Viceton
VicetonThis treatment applies to the following species:
FOR ANIMAL USE ONLY
NOT FOR HUMAN USE
NADA 055-059, Approved by FDA
Chloramphenicol is a broad-spectrum antibiotic shown to have specific therapeutic activity against a wide variety of organisms. Its activity was first demonstrated in culture filtrates from a species of soil organism collected in Venezuela, later designated as Streptomyces venezuelae. The antibiotic was subsequently isolated from culture filtrates (1), identified chemically (2), and later synthesized (3).
Aqueous solutions of chloramphenicol are neutral in pH. Chloramphenicol is stable for several years at room temperature and forms colorless to yellowish-white crystals in the shape of elongated plates or fine needles. It is only slightly soluble in water, but soluble in alcohol and propylene glycol.
Chloramphenicol is exceptionally stable in the presence of high pH, although it is destroyed at pH’s in excess of 10. Dissolved in distilled water, it can withstand boiling for five hours (1).
At low concentrations, chloramphenicol exerts a bacteriostatic effect on a wide range of pathogenic organisms, including many Gram-positive and Gram-negative bacteria, spirochetes, several rickettsiae and certain large viruses and Mycoplasma (PPLO) (4,5,6,7,8,9,10,11,12,13, and 13a). At high concentrations, it inhibits growth of animal and plant cells.
Chloramphenicol exerts its bacteriostatic action by inhibiting protein synthesis in susceptible organisms. Complete suppression of the assimilation of ammonia and of the incorporation of amino acids, particularly glutamic acid, together with an increased formation of ribonucleic acid (RNA), lead to an inhibition of bacterial growth (4,14,15,16, and 17).
Chloramphenicol antagonizes the actions of such antibiotics as penicillin and streptomycin, which act only on growing cells, but is synergistic to tetracycline, which also acts by inhibiting protein synthesis. (18) It is possible the chloramphenicol would produce similar synergism with other antibiotics which act by inhibiting protein synthesis.
In this respect, the experimentally demonstrated synergistic action between chloramphenicol and gamma-globulin should be mentioned. Clinical observations in man and corresponding investigations in laboratory animals experimentally infected with various pathogenic bacteria have shown that a combination of chloramphenicol with gamma-globulin or specific antisera has a greater therapeutic effect than would be expected from a mere addition of the individual effects (19,20,21, and 22).
Many experiments have revealed that the development of resistance to chloramphenicol is rare compared with that occurring with other important antibiotics. (23,24,25,26,27,28,29,30,31,32,33, and 34) Bacterial resistance may develop some strains against chloramphenicol but has been encountered only infrequently in clinical usage.
Chloramphenicol achieves maximum serum levels very rapidly following oral, intravenous and intraperitoneal administration. Intramuscular injection with chloramphenicol, except certain soluble forms, results in a somewhat delayed absorption and lower serum levels than when given by the oral, intravenous, or intraperitoneal route.
Chloramphenicol diffuses readily into all body tissues, but at different concentrations. Highest concentrations are found in the liver and kidney of dogs indicating that these organs are the main route of inactivation and excretion for the metabolites. The lungs, spleen, heart and skeletal muscles contain concentrations similar to that of the blood (27,35,36,37,38, and 39).
Chloramphenicol reaches significant concentration in the aqueous and vitreous humors of the eye from the blood (4).
A significant difference from other antibiotics is its marked ability to diffuse into the cerebrospinal fluid. Within three to four hours after administration, the concentration in the cerebrospinal fluid has reached, on the average, 50% of the concentration in the serum. If the meninges are inflamed, the percentage may be even higher (4,27,29,40,41,42, and 43).
Chloramphenicol diffuses readily into milk, pleural and ascitic fluids and crosses the placenta attaining concentrations of about 75% of that of the maternal blood (36 and 44).
Chloramphenicol is rather rapidly metabolized, mainly in the liver, by conjugation with glucuronic acid.
Approximately 55% of a single daily dose can be recovered from the urine of a treated dog. A small fraction of this is in the form of unchanged chloramphenicol (36).
A single intravenous dose of 150 mg/kg (approximately 68 mg/lb) in propylene glycol is the maximum dose tolerated by the dog. (45) No toxic effect was observed when dogs were administered orally, 200 mg/kg (approximately 91 mg/lb) daily for over four months. (40) In the mouse, the LD-50 is 150-250 mg/kg (68 to 114 mg/lb) body weight by intravenous injection and 1,500 mg/kg (approximately 681 mg/lb) by the oral administration. (1 and 46).
Chloramphenicol Tablets are recommended for oral treatment of the following conditions in dogs:
- Bacterial pulmonary infections caused by susceptible microorganisms such as: Staphylococcus aureus, Streptococcus pyogenes and Brucella bronchiseptica.
- Infections of the urinary tract caused by susceptible microorganisms such as: Escherichia coli, Proteus vulgaris, Corynebacterium renale, Streptococcus spp. and hemolytic Staphylococcus.
- Enteritis caused by susceptible microorganisms such as: E. coli, Proteus spp., Salmonella spp., and Pseudomonas spp.
- Infections associated with canine distemper caused by susceptible microorganisms such as: B. bronchiseptica, E. coli, P. aeruginosa, Proteus spp., Shigella spp. and Neisseria catarrhalis.
Additional adjunctive therapy should be used when indicated. Most susceptible infectious disease organisms will respond to chloramphenicol therapy in three to five days when the recommended dosage regime is followed. If no response to chloramphenicol therapy is obtained in three to five days, discontinue its use and review the diagnosis. Also, a change of therapy should be considered.
Laboratory tests should be conducted including in vitro culturing and susceptibility tests on samples collected prior to treatment.
Because of potential antagonism, chloramphenicol should not be administered simultaneously with penicillin or streptomycin.
NOT FOR USE IN ANIMALS WHICH ARE RAISED FOR FOOD PRODUCTION. CHLORAMPHENICOL PRODUCTS SHOULD NOT BE ADMINISTERED IN CONJUNCTION WITH OR 2 HOURS PRIOR TO THE INDUCTION OF GENERAL ANESTHESIA WITH PENTOBARBITAL BECAUSE OF PROLONGED RECOVERY.
CHLORAMPHENICOL PRODUCTS SHOULD NOT BE ADMINISTERED TO DOGS MAINTAINED FOR BREEDING PURPOSES. SOME EXPERIMENTS INDICATE THAT CHLORAMPHENICOL CAUSES IN EXPERIMENTAL ANIMALS, PARTICULARLY IN FEMALES, SIGNIFICANT DISORDERS IN MORPHOLOGY AS WELL AS IN FUNCTION OF THE GONADS.
HAZARDS AND PRECAUTIONS:
1. This antibiotic contains a chemical structure (nitrobenzene group) that is characteristic of a group of drugs long known to depress hematopoietic activity of the bone marrow (54).
2. In vitro-tissue culture studies using canine bone marrow cells have demonstrated that extremely high concentrations of chloramphenicol inhibit both uptake of iron by the nucleated red cells and incorporation of iron into heme (55).
3. Chloramphenicol products should not be administered in conjunction with or two hours prior to the induction of general anesthesia with pentobarbital because of prolonged recovery time.
4. Chloramphenicol products should not be administered to dogs maintained for breeding purposes. Some experiments indicate that chloramphenicol causes, in experimental animals, particularly females, significant disorders in morphology as well as in function of the gonads.
Certain individual dogs may exhibit transient vomiting or diarrhea after an oral dose of 25 mg/lb body weight (49).
Dosage and Administration
Dogs - 25 mg/lb body weight every 6 hours for oral administration.
Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Keep out of reach of children.
Restricted Drug (California) - Use Only as Directed
Store at 20°-25°C (68°-77°F), with excursions permitted to 15°-30°C (59°-86°F).
Bottles of 500’s
Bottles of 500’s
Bottles of 100’s
1. Ehrlich, J., Q.R. Bartz, R.M. Smith, D.A. Joslyn and P.R. Burkholder (1947): Science 106, 127.
2. Rebstock, M.C., H.M. Crooks, Jr., J. Controulis and Q.R. Bartz (1949): J. Amer. Chem. Soc. 71, 2458-2462.
3. Controulis, J., M.C. Rebstock and H.M. Crooks, Jr. (1949): J. Amer. Chem. Soc. 71, 2463-2468.
4. Barber, M. and L.P. Garrod (1963): Antibiotic and Chemo-therapy. E. & S. Livingston, Edinburgh, London: 116 to 128.
5. Christie, A.B. (1963): Practitioner 191, 588-593.
6. Lange, A. and E. Vogel (1958): Z. Hyg. infektionshrankh. 144, 555-563. Ref.: Landw. Zbl. Abt. IV, 5, 1960, 2188.
7. Schirmer, R.C., F.E. Eades and J.P. Newman (1952): Vet. Med. 46, 485-490 Ref.: Vet. Rec. 64, 1952, 597.
8. Smadel, J.E. and E.B. Jackson (1947): Science 106, 418-419.
9. Zettl, K. (1960): Vet.-Med. Nachr., 28-35.
10. Godzeski, C.W. and D.E. Pavey (1965): Nature 205, No. 4975, 1017 to 1018.
11. Hille, G. and E. Ludwig (1964): Mh. Vet.-Med. 19, 704-708.
12. Hubrig, Th. and D. Schimmel (1965): Mh. Vet.-Med. 20, 171-174.
13. Schimmel, D. and Th. Hubrig (1965): Mh. Vet.-Med. 20, 334-338.
13a.Hagen, Wm. A. and Bruner, D.W. (Third Edition, 1957): The Infectious Diseases of Domestic Animals, Cornell University Press. 1479.
14. Brock, Th. D. (1963): J. Bact. 85, 527-531.
15. Brock, T.D. Chloramphenicol, Bacterial. Rev. 25: 32-48, 1961.
16. Saurat, P. and R. Lautie (1959): Rev. Med. Veterin. 22, 689-701.
17. Schaub, F. (1962): Schweiz, Arch. Tierheilk, 104, 373-384.
18. Reedy, R.J., W.W. Wright, E.J. Oswald and M. Ostrolenk (1958): Antibiot. Ann. 1957/58, 745-750.
19. Fisher, M.W. (1957): Antib. Chemoth. 7, 315-321.
20. Manning, M.C., L.A. Gagliardi and M.W. Fisher (1958): Antibiot. Ann. 1957/58, 566-571.
21. Reedy, R.J., E.J. Oswald and W.W. Wright (1958): Antibiot. Ann. 1957/58, 581-584.
22. Waisbren, B.A. (1957): Antib. Chemoth. 7, 322-333.
23. Beseth, L. (1963): Nord. Vet.-Med. 15, 745-754.
24. Gedek, W., R. Dunkel and L. Kotter (1964): Tierarztl, Umsch. 19, 337-340.
25. Kettner, H. and A. Braunsteiner (1960): Tierarztl, Umsch. 15, 249-255.
26. Kortum, H. (1963): Vet. Med. Diss. Munchen.
27. Kraft, H. (1960): Tierarztl, Umsch. 15, 58-60.
28. Kraft, H. (1962): Tierarztl, Umsch. 17, 278-280.
29. Lettow, E. (1954): Tierarzti, Umsch. 9, 227-230.
30. Manten, A., E.H. Kampelmacher and P.A.M. Guinee (1963): T. Dierganeesk. 88, 411-417.
31. Palyusik, M. (1963): Mag. allator. Lapja 18, 356-357. Ref.: Vet. Bull. 34, 1964, 317.
32. Ramsay, C.H. and P.R. Edwards (1961): Appl. Microbiolog. 9, 389-391.
33. Smith, H.W. (1954): Vet. Rec. 66, 42-43.
34. Smith, W.H. and WE. Crabb (1956): Vet. Rec. 68, 274-277.
35. English, P.B. and A.A. Seawright (1961): Aust. Vet. J. 37, 9-13.
36. Glazko, A.J., L.M. Wolf, W.A. Dill and A.C. Bratton, Jr. (1949): J. Pharmacol. exp. Ther. 96, 445-449.
37. Glazko, A.J., H.E. Carnes, A. Kazenko, L.M. Wolf and T.F. Reutner (1958): Antibiot. Ann. 1957/58, 792-802.
38. Eads, F.E., A.J. Glazko, L.M. Wolf, J. Erlich and M. Galbraith (1952): Amer. J. Vet. Res. 13, 204-206.
39. Leopold, I.H., Nichols, A.C. and Voegl, A.W, Penetration of Chloramphenicol U.S.P. (Chloromycetin) into the Eye. Arch. Ophth., 44:22, 1950.
40. Gruhzit, O.M., R.A. Fisken, T.F. Reutner and E. Martino (1949): J. Clin. Invest. 28, 943-951.
41. McCrumb, Jr., F.R., M.J. Snyder and W.J. Hicken (1958): Antibiot. Ann. 1957/58, 837-841.
42. Ross, S.H. Bischoff, W. Preissner and W. Orr (1949): J. Clin. Invest. 28, 1050.
43. Roy, T.E., E. Krieger, G. Craig, D. Cohen, G.A. McNaughton and N. Silverhorne (1952): Antib. Chemoth. 2, 505-516.
44. Walter, M. and L. Heilmeyer (1954): Antibiotika-Fibel. Georg Thieme Verlag, Stuttgart, 1954.
45. Ehrlich, J. Chloramphenicol. Encyclopedia of Chemical Technology. 4:928-936, 1964.
46. Cheymol, J. (1955): Arzneimittel Forsch. 5, 1-9.
47. Smith, R.M., D.A. Joslyn, O.M. Gruhzit, I.W. McLean, M.A. Penner and J. Ehrlich (1948): J. Bact. 55, 425-448.
48. Van Looveren, L.J. (1958): Schweiz. Arch. Tierheilk. 100, 459-467.
49. Sogtrop, H.H. (1956): Tierarztl, Umsch. 11, 257-261.
50. Hrenoff, A.K. (1962): Med. exp. 6, 118-122.
51. Nelson, A.A. and J.L. Radomski (1954): Antib. Chemoth 4, 1174-1180.
52. Reutner, T.F., R.E. Maxwell, K.E. Weston and J.K. Weston (1955): Antib. Chemoth. 5, 679-711.
53. Weston, J.D., T.F. Reutner, R.Q. Thompson and R.E. Maxwell (1954): Fed. Proc. 13, 416.
54. Jones, L.M., Veterinary Pharmacology and Therapeutics, 3rd Edition, Iowa State University Press, Ames, Iowa, 539-542, 1965.
55. Ward, H.P., The Effect of Chloramphenicol on RNA and Heme Synthesis in Bone Marrow Cultures. Journ. Lab & Clinical Med., 68: 403, 1966.
56. The Merck Veterinary Manual, 2nd Edition, Merck & Co., Inc., Rahway, N.J., 522-524, 1961.
Manufactured by: Bimeda, Inc., Le Sueur, MN 56058
Bimeda, Inc. is a division of Cross Vetpharm Group Ltd.
® Registered Trademark of Bimeda, Inc.
500 Tablets (250 mg Each)
500 Tablets (500 mg Each)
100 Tablets (1 Gram Each)
8VIC002 REV. 06/11
NAC No.: 13990457
Div. Cross Vetpharm Group, Ltd.
ONE TOWER LANE-SUITE 2250, OAKBROOK TERRACE, IL, 60181
|Every effort has been made to ensure the accuracy of the Viceton information published above. However, it remains the responsibility of the readers to familiarize themselves with the product information contained on the US product label or package insert.|
Copyright © 2013 North American Compendiums. Updated: 2013-09-18